Table 1 International Breast Cancer Study Group tailored treatment trials (trials presented in this report)
From: Clinical trial update: International Breast Cancer Study Group
IBCSG Trial | Population | Activation | Target accrual | Comparison(s) |
|---|---|---|---|---|
CM-maintenance IBCSG 22-00 | Endocrine non-responsive | November 2000 | 900 | Induction CT versus Induction CT → CM maintenance |
CASA IBCSG 32-05 | Endocrine non-responsive, older, not suitable for standard CT | August 2005 | 1,296 | Option 1: PLD versus nil Option 2: PLD versus low dose CM |
SOFT IBCSG 24-02 | Premenopausal at randomization | August 2003 | 3,000 | Tamoxifen alone versus OFS + tamoxifen versus OFS + exemestane |
TEXT IBCSG 25-02 | Should get OFS at start | August 2003 | 1,845 | Triptorelin ± CT + tamoxifen versus triptorelin ± CT + exemestane |
PERCHE IBCSG 26-02 | Should get OFS at start, lower risk | August 2003 | 1,750 | OFS + (tamoxifen or exemestane) versus OFS + CT + (tamoxifen or exemestane) |